# Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

> **NCT00749320** · NA · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 32 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **OTHER:** Arterial Spin Labeling Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT00749320
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-02-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00749320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00749320, "Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00749320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*